| Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant. BM Longenecker, M Reddish, R Koganty, GD MacLean Annals of the New York Academy of Sciences 690, 276-291, 1993 | 781 | 1993 |
| Safety and Immunogenicity of 26-Valent Group A Streptococcus Vaccine in Healthy Adult Volunteers SA McNeil, SA Halperin, JM Langley, B Smith, A Warren, GP Sharratt, ... Clinical Infectious Diseases 41 (8), 1114-1122, 2005 | 385 | 2005 |
| Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2 B Agrawal, MJ Krantz, MA Reddish, BM Longenecker Nature medicine 4 (1), 43-49, 1998 | 372 | 1998 |
| Immunogenicity of a 26-valent group A streptococcal vaccine MC Hu, MA Walls, SD Stroop, MA Reddish, B Beall, JB Dale Infection and immunity 70 (4), 2171-2177, 2002 | 318 | 2002 |
| The breast mucin MUC1 as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer LH Regimbald, LM Pilarski, BM Longenecker, MA Reddish, ... Cancer research 56 (18), 4244-4249, 1996 | 295 | 1996 |
| Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin MR Price, PD Rye, E Petrakou, A Murray, K Brady, S Imai, S Haga, ... Tumor Biology 19 (Suppl. 1), 1-20, 1998 | 278 | 1998 |
| Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant GD MacLean, M Reddish, RR Koganty, T Wong, S Gandhi, M Smolenski, ... Cancer Immunology, Immunotherapy 36, 215-222, 1993 | 236 | 1993 |
| Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn … GD MacLean, MA Reddish, RR Koganty, BM Longenecker Journal of Immunotherapy 19 (1), 59-68, 1996 | 219 | 1996 |
| Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial KL Kotloff, M Corretti, K Palmer, JD Campbell, MA Reddish, MC Hu, ... Jama 292 (6), 709-715, 2004 | 195 | 2004 |
| Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide GD MacLean, DW Miles, RD Rubens, MA Reddish, BM Longenecker Journal of Immunotherapy 19 (4), 309-316, 1996 | 193 | 1996 |
| Anti‐MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide MA Reddish, GD MacLean, RR Koganty, J Kan‐Mitchell, V Jones, ... International journal of cancer 76 (6), 817-823, 1998 | 167 | 1998 |
| Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope … BM Sandmaier, DV Oparin, LA Holmberg, MA Reddish, GD MacLean, ... Journal of Immunotherapy 22 (1), 54-66, 1999 | 153 | 1999 |
| Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses HH Guan, W Budzynski, RR Koganty, MJ Krantz, MA Reddish, JA Rogers, ... Bioconjugate chemistry 9 (4), 451-458, 1998 | 146 | 1998 |
| Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary … L Ding, EN Lalani, M Reddish, R Koganty, T Wong, J Samuel, ... Cancer Immunology, Immunotherapy 36, 9-17, 1993 | 145 | 1993 |
| A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer DW Miles, KE Towlson, R Graham, M Reddish, BM Longenecker, ... British journal of cancer 74 (8), 1292-1296, 1996 | 129 | 1996 |
| Immune sera and monoclonal antibodies define two configurations for the sialyl Tn tumor antigen S Zhang, LA Walberg, S Ogata, SH Itzkowitz, RR Koganty, M Reddish, ... Cancer research 55 (15), 3364-3368, 1995 | 129 | 1995 |
| Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope® sialyl-Tn-KLH cancer vaccine in active … MA Reddish, GD MacLean, S Poppema, A Berg, BM Longenecker Cancer Immunology, Immunotherapy 42, 303-309, 1996 | 109 | 1996 |
| Immunogenicity and antitumor activity of a liposomal MUC1 peptide‐based vaccine J Samuel, WA Budzynski, MA Reddish, L Ding, GL Zimmermann, ... International journal of cancer 75 (2), 295-302, 1998 | 108 | 1998 |
| Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE® STn-KLH cancer vaccine LA Holmberg, DV Oparin, T Gooley, K Lilleby, W Bensinger, MA Reddish, ... Bone marrow transplantation 25 (12), 1233-1241, 2000 | 104 | 2000 |
| Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl) cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against … G Ragupathi, L Howard, S Cappello, R Rao Koganty, D Qiu, ... Cancer Immunology, Immunotherapy 48, 1-8, 1999 | 104 | 1999 |
